Abstract
Unprecedented. This is the closest and most appropriate word to describe the COVID-19 pandemic, which the world has been experiencing with pain and fear. The first case of pneumonia-like symptoms of unknown etiology appeared presumably in November 2019, with the subsequent official report to the WHO by the Chinese authorities on December 31, 2019. China’s first confirmed death from the virus occurred on January 11, 2020, when a 61-year-old male resident of Hubei, the capital of Wuhan Province, died. Within a month, the COVID-19 death toll surpassed 1,000 (February 10, 2020). Accordingly, just 30 days after the initial report, the coronavirus outbreak was called a “public health emergency of international concern” by the WHO, the organization’s highest alert level. Unfortunately, the WHO soon declared the COVID-19 outbreak a pandemic (March 11, 2020). Within a year of viral emergence, and by December 2020, more than 80 million confirmed cases had been reported worldwide. Infections increased exponentially over the following year. As of February 11, 2022, over 400 million cases have been reported, with nearly 6 million deaths, an unprecedented rate of spread across borders.
Article PDF
Avoid common mistakes on your manuscript.
References
Choi, J. and Kim, J.O. 2022. Middle East Respiratory Syndrome coronavirus vaccine development: updating clinical studies using platform technologies. J. Microbiol. 60. 238–246.
Kim, Y.I., Casel, M.A.B., and Choi, Y.K. 2022a. Transmissibility and pathogenicity of SARS-CoV-2 variants in animal models. J. Microbiol. 60. 255–267.
Kim, C., Kim, J.D., and Seo, S.U. 2022b. Nanoparticle and virus-like particle vaccine approaches against SARS-CoV-2. J. Microbiol. 60. 335–346.
Kim, N.E. and Song, Y.J. 2022. Coordinated regulation of interferon and inflammasome signaling pathways by SARS-CoV-2 proteins. J. Microbiol. 60. 300–307.
Lee, M.H. and Kim, B.J. 2022. COVID-19 vaccine development based on recombinant viral and bacterial vector systems: combinatorial effect of adaptive and trained immunity. J. Microbiol. 60. 321–334.
Mattoo, S.S. and Myoung, J. 2021. A promising vaccination strategy against COVID-19 on the horizon: heterologous immunization. J. Microbiol. Biotechnol. 31. 1601–1614.
Mattoo, S.S. and Myoung, J. 2022. T cell responses to SARS-CoV-2 in humans and animals. J. Microbiol. 60, 276–289.
Oh, S.J. and Shin, O.S. 2022. SARS-CoV-2-mediated evasion strategies for antiviral interferon pathways. J. Microbiol. 60. 290–299.
Park, U. and Cho, N.H. 2022. Protective and pathogenic role of humoral responses in COVID-19. J. Microbiol. 60. 268–275.
Park, J., Kim, J., and Jang, Y.S. 2022a. Current status and perspectives on vaccine development against dengue virus infection. J. Microbiol. 60. 247–254.
Park, J., Park, R., Jang, M., Park, Y.I., and Park, Y. 2022b. Coronavirus enzyme inhibitors-experimentally proven natural compounds from plants. J. Microbiol. 60. 347–354.
Park, H., Park, M.S., Seok, J.H., You, J., Kim, J., Kim, J., and Park, M.S. 2022c. Insights into the immune responses of SARS-CoV-2 in relation to COVID-19 vaccines. J. Microbiol. 60. 308–320.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Myoung, J. Two years of COVID-19 pandemic: where are we now?. J Microbiol. 60, 235–237 (2022). https://doi.org/10.1007/s12275-022-1679-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12275-022-1679-x